Repligen (NASDAQ:RGEN) Stock Rating Upgraded by Royal Bank Of Canada

Repligen (NASDAQ:RGEN) was upgraded by stock analysts at Royal Bank Of Canada to a “moderate buy” rating in a note issued to investors on Thursday,Zacks.com reports.

RGEN has been the topic of several other reports. HC Wainwright raised their price objective on Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, March 23rd. Rothschild & Co Redburn set a $160.00 target price on Repligen and gave the company a “buy” rating in a research report on Friday, April 17th. JPMorgan Chase & Co. decreased their target price on Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Roth Mkm began coverage on Repligen in a research report on Friday, April 17th. They set a “buy” rating and a $160.00 target price for the company. Finally, Canaccord Genuity Group decreased their target price on Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a research report on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $166.15.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $102.87 on Thursday. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. The stock’s fifty day simple moving average is $118.96 and its two-hundred day simple moving average is $142.18. Repligen has a 1-year low of $100.99 and a 1-year high of $175.77. The stock has a market cap of $5.80 billion, a PE ratio of 114.30, a price-to-earnings-growth ratio of 1.99 and a beta of 1.09.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The business had revenue of $194.26 million for the quarter, compared to analysts’ expectations of $192.05 million. During the same period last year, the business earned $0.39 EPS. The business’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, analysts forecast that Repligen will post 1.99 EPS for the current fiscal year.

Institutional Investors Weigh In On Repligen

Large investors have recently added to or reduced their stakes in the company. Measured Wealth Private Client Group LLC purchased a new stake in Repligen in the 3rd quarter worth about $29,000. Bayforest Capital Ltd purchased a new stake in Repligen in the 4th quarter worth about $32,000. Rachor Investment Advisory Services LLC purchased a new stake in Repligen in the 4th quarter worth about $33,000. Los Angeles Capital Management LLC purchased a new stake in Repligen in the 4th quarter worth about $36,000. Finally, CWM LLC increased its holdings in Repligen by 67.2% in the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 135 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.